Literature DB >> 12435697

Energy-dependent accumulation of norfloxacin and porin expression in clinical isolates of Klebsiella pneumoniae and relationship to extended-spectrum beta-lactamase production.

Luis Martínez-Martínez1, Alvaro Pascual, María del Carmen Conejo, Isabel García, Providencia Joyanes, Antonio Doménech-Sánchez, Vicente Javier Benedí.   

Abstract

The relationships between porin deficiency, active efflux of fluoroquinolones, and extended-spectrum beta-lactamase (ESBL) production were determined for 53 clinical isolates of Klebsiella pneumoniae. Thirty-two ESBL-positive strains (including 22 strains expressing porins and 10 strains lacking porins) and 21 ESBL-negative strains were evaluated. Active efflux of norfloxacin was defined as a >/=50% increase in the accumulation of norfloxacin in the presence of carbonyl cyanide m-chlorophenylhydrazone (CCCP) in comparison with the corresponding basal value in the absence of CCCP. The quinolone resistance-determining regions of both gyrA and parC from 13 strains, representing all isolates with different porin profiles and with or without active efflux, were determined. Porin loss was significantly more common among ESBL-positive strains (10 of 32 [31.2%]) than among ESBL-negative strains (0 of 2 [0%]) (P < 0.01). Active efflux was observed in 7 of 10 (70%) strains lacking porins and in 4 of 43 (9.3%) strains producing porins (P < 0.001). The 11 strains showing active efflux corresponded to 3 of 21 (14.3%) ESBL-negative strains and 8 of 32 (25.5%) ESBL-positive strains (P > 0.05). Basal values of norfloxacin accumulation were higher in strains lacking active efflux than in those that had this mechanism (P < 0.05). In the absence of topoisomerase changes, the contribution of either porin loss or active efflux to fluoroquinolone resistance in K. pneumoniae was negligible. It is concluded that among K. pneumoniae strains of clinical origin, porin loss was observed only in those producing ESBL, and that a significant number of porin-deficient strains also expressed active efflux of norfloxacin. In terms of fluoroquinolone resistance, both mechanisms are significant only in the presence of topoisomerase modifications.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12435697      PMCID: PMC132737          DOI: 10.1128/AAC.46.12.3926-3932.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

Review 1.  AcrAB and related multidrug efflux pumps of Escherichia coli.

Authors:  H Nikaido; H I Zgurskaya
Journal:  J Mol Microbiol Biotechnol       Date:  2001-04

2.  High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA.

Authors:  A Mazzariol; Y Tokue; T M Kanegawa; G Cornaglia; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

3.  Relationship between outer membrane alterations and susceptibility to antimicrobial agents in isogenic strains of Klebsiella pneumoniae.

Authors:  S Hernández-Allés; M d Conejo; A Pascual; J M Tomás; V J Benedí; L Martínez-Martínez
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

4.  Cloning and sequence analysis of gyrA gene of Klebsiella pneumoniae.

Authors:  G P Dimri; H K Das
Journal:  Nucleic Acids Res       Date:  1990-01-11       Impact factor: 16.971

5.  A comparison of methods used for measuring the accumulation of quinolones by Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  P G Mortimer; L J Piddock
Journal:  J Antimicrob Chemother       Date:  1991-11       Impact factor: 5.790

6.  AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants.

Authors:  H Okusu; D Ma; H Nikaido
Journal:  J Bacteriol       Date:  1996-01       Impact factor: 3.490

7.  Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction.

Authors:  S P Cohen; L M McMurry; D C Hooper; J S Wolfson; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

8.  Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.

Authors:  D L Paterson; L Mulazimoglu; J M Casellas; W C Ko; H Goossens; A Von Gottberg; S Mohapatra; G M Trenholme; K P Klugman; J G McCormack; V L Yu
Journal:  Clin Infect Dis       Date:  2000-03       Impact factor: 9.079

9.  Mechanism of plasmid-mediated quinolone resistance.

Authors:  John H Tran; George A Jacoby
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-09       Impact factor: 11.205

10.  Multidrug resistance in Klebsiella pneumoniae: a novel gene, ramA, confers a multidrug resistance phenotype in Escherichia coli.

Authors:  Anthony M George; Ruth M Hall; H W Stokes
Journal:  Microbiology (Reading)       Date:  1995-08       Impact factor: 2.777

View more
  25 in total

1.  Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients.

Authors:  Jesús Rodríguez-Baño; Maria Dolores Navarro; Luisa Romero; Luis Martínez-Martínez; Miguel A Muniain; Evelio J Perea; Ramón Pérez-Cano; Alvaro Pascual
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

2.  Structural and biochemical analysis of the pentapeptide repeat protein EfsQnr, a potent DNA gyrase inhibitor.

Authors:  Subray S Hegde; Matthew W Vetting; Lesley A Mitchenall; Anthony Maxwell; John S Blanchard
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

3.  Prevalence and role of efflux pump activity in ciprofloxacin resistance in clinical isolates of Klebsiella pneumoniae.

Authors:  S Aathithan; G L French
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-02-01       Impact factor: 3.267

4.  Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.

Authors:  María Pérez-Vázquez; Federico Román; Silvia García-Cobos; José Campos
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

Review 5.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

6.  Quinolones sensitize gram-negative bacteria to antimicrobial peptides.

Authors:  Miguel A Campos; Pau Morey; José A Bengoechea
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

7.  Role of AcrR and ramA in fluoroquinolone resistance in clinical Klebsiella pneumoniae isolates from Singapore.

Authors:  T Schneiders; S G B Amyes; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

8.  Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance.

Authors:  Antonio Doménech-Sánchez; Luis Martínez-Martínez; Santiago Hernández-Allés; María del Carmen Conejo; Alvaro Pascual; Juan M Tomás; Sebastián Albertí; Vicente Javier Benedí
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence.

Authors:  Emma Padilla; Enrique Llobet; Antonio Doménech-Sánchez; Luis Martínez-Martínez; José Antonio Bengoechea; Sebastián Albertí
Journal:  Antimicrob Agents Chemother       Date:  2009-10-26       Impact factor: 5.191

10.  Alteration of GyrA amino acid required for ciprofloxacin resistance in Klebsiella pneumoniae isolates in China.

Authors:  Yingmei Fu; Lishuang Guo; Yan Xu; Wenli Zhang; Jiaao Gu; Jianfeng Xu; Xiaobei Chen; Yuehui Zhao; Jiayu Ma; Xinghan Liu; Fengmin Zhang
Journal:  Antimicrob Agents Chemother       Date:  2008-05-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.